Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 6:14 PM ET

Pharmaceuticals

Company Overview of Iroko Pharmaceuticals Inc.

Company Overview

Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...

One Kew Place

150 Rouse Boulevard

Philadelphia, PA 19112

United States

Founded in 2012

71 Employees

Phone:

267-546-3003

Fax:

267-546-3004

Key Executives for Iroko Pharmaceuticals Inc.

Chief Executive Officer and President
Executive Chairman of the Board
Age: 52
Chief Financial Officer and Principal Accounting Officer
Age: 67
Senior Vice President, General Counsel and Secretary
Age: 47
Senior Vice President and Chief Medical Officer
Age: 58
Compensation as of Fiscal Year 2014.

Iroko Pharmaceuticals Inc. Key Developments

Iroko Pharmaceuticals Announces International Regulatory Approval for ZORVOLEX®

Iroko Pharmaceuticals Inc. announced the Republic of Lebanon Ministry of Public Health (MOPH) has approved ZORVOLEX®, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults and osteoarthritis (OA) pain. ZORVOLEX was approved by the U.S. Food and Drug Administration (FDA) in August 2014 for the management of OA pain and in October 2013 for the treatment of mild to moderate acute pain in adults1. This regulatory approval for ZORVOLEX marks an important milestone in the international commercialization strategy for its low dose NSAID portfolio.

Iroko Pharmaceuticals Inc. Announces New Strategic Agreement to Commercialize ZORVOLEX in Australia and New Zealand

Iroko Pharmaceuticals, LLC announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Aspen Pharma Pty Ltd. for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand. Aspen Pharma Pty Ltd. will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.

Iroko Pharmaceuticals Inc. Signs New Strategic Agreement with Landsteiner Scientific, S.A. de C.V to Bring ZORVOLEX(R) to Mexico

Iroko Pharmaceuticals Inc. signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Mexico. Landsteiner Scientific will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S.

Similar Private Companies By Industry

Company Name Region
Momentus Solutions LLC United States
ElixinPharma United States
METAMUNE, iNC United States
Product Quest Manufacturing, LLC United States
Cerep Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iroko Pharmaceuticals Inc., please visit www.iroko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.